Table 1

Demographic and Clinical Characteristics of Cohort

MenWomen
Combination of ceftriaxone + lansoprazole
 n9341,414
 Demographic
 Age, yrs61.3 ± 16.966.5 ± 18.5
 % Race distribution
 White57.352.9
 African American18.920.2
 Other/unknown23.826.9
 QTc, ms458 (398–588)457 (401–571.7)
 % Patients with QTc ≥500 ms19.2716.34
Combination of cefuroxime + lansoprazole
 n107228
 Demographic
 Age, yrs66.1 ± 15.767.6 ± 17.9
 % Race
 White56.160.1
 African American13.114.9
 Other/unknown30.825.0
 QTc, ms450 (393.6–579.4)443.5 (398.7–579.2)
 % Patients with QTc ≥500 ms14.9511.40
Ceftriaxone only
 n5,7346,850
 Demographic
 Age, yrs59.5 ± 17.963.7 ± 19.8
 % Race
 White46.645.1
 African American19.018.4
 Other/unknown34.436.5
 QTc, ms446 (394–566)448 (398–560)
 % Patients with QTc ≥500 ms14.2111.43
Cefuroxime only
 n636957
 Demographic
 Age, yrs61.5 ± 17.666.0 ± 19.3
 % Race
 White54.150.3
 African American20.619.3
 Other/unknown25.330.4
 QTc, ms435 (391.9–552.1)439 (397–551.1)
 % Patients with QTc ≥500 ms11.169.09
Lansoprazole only
 n12,27113,074
 Demographic
 Age, yrs60.0 ± 15.863.1 ± 17.7
 % Race
 White60.854.6
 African American13.916.7
 Other/unknown25.328.7
 QTc, ms443 (395–572)445 (399–569)
 % Patients with QTc ≥500 ms12.8412.07

Values are n, mean ± SD, or median (95% confidence interval).